For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

January 06, 2021

Published: January 06, 2021
Category: Office of the Director
2020 Year End Review

A look back at 2020, a pandemic year that saw tremendous achievements across the CCTG network

This past year has been one of constant challenge within our group, network, country, and the world. Yet despite the disruptions to our daily lives and work, this year has also been one of immense accomplishment.

Read More

December 16, 2020

Published: December 16, 2020
Category: Trials
Trial Activation: HDC1

The HDC1 study: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma has been centrally activated in Canada.

Read More

Published: December 16, 2020
Category: Trials

MAC21 (NCT02927249), A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, has closed to accrual after completion of target accrual.

Read More

Published: December 16, 2020
Category: Group updates
2020 Holiday Hours - CCTG TTDR & BARL

Holiday hours and days of operation for the CCTG central office, CCTG’s Tumour Tissue Data Repository and the Bay Area Research Logistics.

Read More

Published: December 16, 2020
Category: News

Everyone at CCTG would like to congratulate Dr Joseph Connors for his recent appointment to the Order of Canada, as one of 114 Canadian appointees “whose service has shaped our society; whose innovations ignite our imaginations; and whose compassion unites our communities.”  

Read More

Published: December 16, 2020
Category: Publications

As with most events in 2020 the 62nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in.

Read More

Published: December 16, 2020
Category: Publications

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.

Read More

Published: December 16, 2020
Category: Publications
Publication: ALC2

Subanalysis study results for ALC2 (NCT00651261): Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Read More